Skip to main content
. Author manuscript; available in PMC: 2016 Jan 31.
Published in final edited form as: Angew Chem Int Ed Engl. 2015 Nov 23;55(2):807–810. doi: 10.1002/anie.201507634

Figure 2.

Figure 2

VHL-based PROTACs. A) BOS-6-2-2–6-VHL, and B) DAS-6-2-2-6-VHL were incubated with K562 human chronic myelogenous leukemia cells for 24 h. The concentrations of the parent inhibitors are 1μm. As determined by immunoblot, degradation of c-ABL can be observed with DAS-VHL starting at 1μm; however, no degradation of BCR-ABL was observed in any of the VHL-based PROTACs.